[S03AA02, tetracycline, The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Tetracycline.]
[S01XA02, vitamin A, The risk or severity of adverse effects can be increased when Vitamin A is combined with Acitretin.]
[G03AC10, drospirenone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Acitretin.]
[J01AA13, eravacycline, The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Eravacycline.]
[J01AA14, sarecycline, The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Sarecycline.]
[J01AA15, omadacycline, The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Omadacycline.]
[J01AA11, clomocycline, The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Clomocycline.]
[L01EX15, pexidartinib, Acitretin may increase the hepatotoxic activities of Pexidartinib.]
[G03DB05, demegestone, The therapeutic efficacy of Demegestone can be decreased when used in combination with Acitretin.]
[G03AC09, desogestrel, The therapeutic efficacy of Desogestrel can be decreased when used in combination with Acitretin.]
[G03DB08, dienogest, The therapeutic efficacy of Dienogest can be decreased when used in combination with Acitretin.]
[M09AX11, palovarotene, The risk or severity of adverse effects can be increased when Acitretin is combined with Palovarotene.]
[J01AA01, demeclocycline, The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Demeclocycline.]
[L02AA01, diethylstilbestrol, The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Acitretin.]
[J01AA02, doxycycline, The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Doxycycline.]
[J01AA12, tigecycline, The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Tigecycline.]
[G03CA03, estradiol, The therapeutic efficacy of Estradiol can be decreased when used in combination with Acitretin.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Acitretin.]
[V03AZ01, ethanol, Ethanol may increase the teratogenic activities of Acitretin.]
[G03XA02, gestrinone, The therapeutic efficacy of Gestrinone can be decreased when used in combination with Acitretin.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Acitretin.]
[J01AA04, lymecycline, The risk or severity of pseudotumor cerebri can be increased when Lymecycline is combined with Acitretin.]
[G03DC03, lynestrenol, The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Acitretin.]
[J01AA05, methacycline, The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Metacycline.]
[L04AX03, methotrexate, The risk or severity of liver damage can be increased when Acitretin is combined with Methotrexate.]
[J01AA08, minocycline, The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Minocycline.]
[G03DC02, norethindrone, The therapeutic efficacy of Norethisterone can be decreased when used in combination with Acitretin.]
[G03AC07, norgestrienone, The therapeutic efficacy of Norgestrienone can be decreased when used in combination with Acitretin.]
[S01AA04, oxytetracycline, The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Oxytetracycline.]
[G03DB06, chlormadinone, The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Acitretin.]
[J01AA09, rolitetracycline, The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Rolitetracycline.]
[N03AG01, valproic acid, Valproic acid may increase the Pseudotumor Cerebri activities of Acitretin.]
